Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy
| Autor: | Songkai Yan, Andreas Tiede, Johannes Oldenburg, Geraldine Maro, Girishanthy Krishnarajah |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Drug Utilization Adult Male medicine.medical_specialty Adolescent Recombinant Fusion Proteins Treatment outcome Hemorrhage 030204 cardiovascular system & hematology Hemophilia B law.invention Factor IX 03 medical and health sciences Young Adult 0302 clinical medicine Pharmacotherapy law Internal medicine medicine Humans 030212 general & internal medicine Child Aged Retrospective Studies business.industry Half-life Human albumin General Medicine Middle Aged Fusion protein Child Preschool Recombinant DNA business medicine.drug Half-Life |
| Zdroj: | Current medical research and opinion. 36(1) |
| ISSN: | 1473-4877 |
| Popis: | Objective: An extended half-life factor IX (FIX) fusion protein linking recombinant FIX with recombinant human albumin (rIX-FP), indicated for the treatment of hemophilia B, was approved by the Eur... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|